Overview
- In an extension of its Phase 2 trial, Amgen said a large majority of patients who had lost at least 15% of body weight maintained that loss for another 52 weeks on lower monthly or quarterly doses.
- The second year of treatment was described as well tolerated, with low rates of nausea and vomiting and no new safety signals reported.
- A separate 24-week study in people with Type 2 diabetes found once-monthly dosing produced clinically meaningful reductions in HbA1c and body weight.
- MariTide uses an antibody–peptide design that activates GLP-1 receptors while blocking GIP receptors, distinguishing it from current weekly injectables.
- Amgen said multiple Phase 3 trials are underway, including a 72-week study testing three doses, and the CEO highlighted the potential for monthly or even quarterly use to address adherence.